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Abstract
Iron is an essential element for cell growth and development, contributing to DNA synthesis and regulating the G1-phase to S-phase
transition. Moreover, iron is important for the virulence of the majority of microorganisms, and the function of the genes regulating
iron uptake is coupled with the manifestations of the virulence phenotype. All fungi elaborate speciﬁc uptake mechanisms to sequester
iron, and most commonly produce small molecules with high afﬁnity for iron, the siderophores. The importance of iron appears to be
particularly high for Zygomycetes, which grow abundantly in iron-rich media, and all the known predisposing factors for zygomycosis
have, as a common feature, the increased availability of free iron. Among the known iron chelators, deferoxamine supports the growth
of Zygomycetes because it acts as xenosiderophore, delivering iron to iron-uptaking molecules of these species. Conversely, the newer
iron chelators deferiprone and deferasirox do not exhibit similar activity, apparently because they share higher afﬁnity constants for iron
and, as a result, deprive the fungi of iron, inhibiting their growth. This activity has been documented in various culture systems and in
many animal models of zygomycosis, and therefore suggests that these drugs might be used as adjuvant treatment for systemic zygomy-
cosis. There are few case reports in which the newer iron chelators have been used as antifungals, and their possible beneﬁt must be
veriﬁed in a prospective randomized trial.
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Introduction
Iron is a key element for the growth and development of
any cell or organism. Eukaryotic cells, entering the S-phase
of the cell cycle, upregulate transferrin receptor-1 expression
to obtain iron from the extracellular environment. Iron is a
cofactor of ribonucleotide reductase, which is necessary for
DNA synthesis, and of the oxygen transporters in mitochon-
dria, and activates the cyclin/cyclin-dependent kinase com-
plexes, thus regulating the progression from the G1-phase to
the S-phase of the cell cycle.
The Role of Iron in Cell Growth
Low levels of intracellular Fe3+ increase the activity of the
cyclin-dependent kinase inhibitor p21CIP1/WAF1, thus delay-
ing or inhibiting transition to S-phase. As a result, Bcl-2 is
downregulated and Bax levels are increased, conditions that
activate caspase-3, caspase-8, and caspase-9, and lead to
apoptosis and cell death [1].
Iron is essential for the virulence of all infectious microor-
ganisms. The low concentration of free iron (non-transferrin-
bound iron) in plasma and other tissues represents a major
protective mechanism against invading pathogens. An extre-
mely low level (10)18 M) is maintained because of the action
of two major iron-binding proteins, transferrin and lactofer-
rin, which are partly saturated with iron (usually 30% and,
in general, <50%) and seek to incorporate ferric iron [2].
Lactoferrin is produced and released by many cell types,
including neutrophils and monocytes, and represents the fun-
gistatic factor of human serum, milk, and other ﬂuids [3].
Pathogens require 10)6 to 10)7 M iron for growth, and,
therefore, serum and other biological ﬂuids are normally fun-
gistatic for all fungi, including Candida spp., Aspergillus spp.,
and the Zygomycetes [4]. The fungistatic properties of
human serum in vitro are completely abolished by the addi-
tion of exogenous iron, and Candida albicans is capable of
growth in serum cultures with transferrin saturation >90%,
but not when serum has normal transferrin saturation.
Thus, pathogenic microorganisms have developed very
sophisticated methods to obtain, or rather ‘steal’, iron from
their hosts, establishing a strong competition for iron with
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them. The outcome of the ‘iron battle’ will determine
whether there will be a clinically apparent infection, a carrier
state, or elimination of the invader. Diseases and conditions
accompanied by a high iron burden have been associated
with increased susceptibility to infections. Among these are
tissue hypoxia, diabetic ketoacidosis, acidosis of any other
cause, tissue damage and necrosis, post-traumatic states or
those induced by chemotherapy, haemochromatosis, liver
disease, and cancer. There are three sources of iron for
microbial growth: proteinic iron from the iron-carrying pro-
teins (ferritin, transferrin, etc.), haem iron following lysis of
red blood cells, and tissue iron, which is available following
tissue damage [2,4].
Patients with acute myelogenous leukaemia or other
malignancies commonly have an excess of iron, as demon-
strated by elevated serum transferrin saturation. The levels
of iron and, particularly, non-transferrin-bound iron are fur-
ther increased following chemotherapy [5], either because of
tissue damage or, in some cases, as a result of circulating
iron complexes. The complexes are produced by the leukae-
mic cells and liberated following their death, induced by che-
motherapy. All of the above render leukaemic neutropenic
patients particularly vulnerable to fungal infections. C. albicans,
for example, grows readily in leukaemic serum with high
transferrin saturation. Chemotherapy also elevates free
serum iron levels in patients with gastric cancer and non-
Hodgkin’s lymphoma [4].
Finally, liver iron overload in patients undergoing ortho-
topic liver transplantation is a predisposing factor for the
development of invasive fungal infections, as these infec-
tions occur three times more commonly among trans-
planted patients with sustainable levels of iron in the liver
[6].
Iron and Fungal Development
Iron uptake by fungi is achieved by speciﬁc transport sys-
tems, in which an initially ferric form is reduced to ferrous
iron through the action of speciﬁc cell surface reductases
(ferroxidases). Ferrous iron is then internalized by three dif-
ferent mechanisms. The ﬁrst depends on the fact that iron-
containing ferroxidases have a high afﬁnity for a speciﬁc type
of fungal transport proteins, the permeases. The iron perme-
ase–ferroxidase complexes (Ftr1–Fet3) easily transverse the
fungal wall and cell membrane, and iron is therefore pro-
vided intracellularly. There are speciﬁc transcriptional activa-
tors or repressors of the genes of the ferroxidases and
permeases, such as Aft1 and Aft2 in Saccharomyces cerevisiae
or the Cryptococcus iron regulator gene (CIR1) in Cryptococcus
neoformans, which modulate their expression under condi-
tions of iron deprivation. A second mechanism involves the
production of low molecular mass iron-speciﬁc chelators
(siderophores), which are excreted through the fungal wall
in the deferric form, bind iron, and then are taken up by the
fungi. Finally, a third mechanism is related to a fungal haem
oxygenase, which takes up iron from haem [7,8].
C. albicans possesses two high-afﬁnity iron permease genes
that are essential for its virulence. Iron permeases are
encoded by iron-responsive genes, which are regulated by
speciﬁc transcriptional modulators. Deletion of these genes
renders mutant strains non-virulent [9]. Conditions of iron
overload enhance the growth of C. albicans and increase the
mortality rate of infected mice. Elevated serum iron levels
have been documented among patients with urogenital candi-
diasis. CIR1 is a gene regulating iron homeostasis, but also
regulates calcium and cAMP signaling, cell wall integrity, and
the expression of all virulence functions, including capsule
and melanin formation and growth at host temperature.
Non-enzymatic reduction of ferric iron by 3-hydroxylanthra-
nilic acid and melanin has been documented in Cryptococcus
neoformans [10].
The expression of permease genes in Aspergillus spp. and
zygomycetes is upregulated during their growth and viru-
lence [11]. The growth and survival of Aspergillus fumigatus
and other species in serum is associated with the removal of
iron from transferrin and other iron-containing proteins
[12]. This is accomplished by the activity of siderophores.
There are two major classes of microbial siderophores, a
list of which is provided in Table 1. Fungal species are capa-
ble of synthesizing many different siderophores; however,
the most important and most commonly found in Aspergillus
and zygomycetes are N¢,N¢,N-triacetylfusarinine C and ferri-
crocin. These substances exhibit extremely high afﬁnity for
iron, and hold it with three bidentate bonds. The high afﬁnity
is speciﬁc for iron, and does not extend to other bivalent
cations. The production of siderophores is enhanced in con-
ditions of iron depletion, and many metabolic steps of their
TABLE 1. Bacterial and fungal siderophores
Hydroxamate class siderophores
N¢,N¢,N-triacetylfusarinine C*
Rhodorotulic acid
Aerobactin
Enterobacin
Ferrichrome class siderophores
Ferricrocin#
Ferrirubin
Ferrichrysin
Ferrirhodin
Asperchromes
Ferrichrome
Fusigen
*Most common, #second most common, bacterial siderophores.
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biosynthesis have been characterized. Siderophores have
higher binding constants for iron than transferrin and lacto-
ferrin, and thus are capable of detaching iron from these
proteins. Their biosynthesis is conﬁned to bacterial and fun-
gal cells, and their expression increases the virulence of
these species [13]. Aspergillus uses two iron uptake mecha-
nisms, the reductase–permease complex and the sidero-
phore-assisted mechanism [14]. The latter has been
demonstrated in vitro, as holotransferrin, but not apotransfer-
rin, supports the growth of Aspergillus spp. in iron-depleted
serum culture systems. In such systems, siderophore produc-
tion becomes evident following 10 h of incubation and
reaches a peak at 20 h [12].
Nevertheless, not all species and strains produce sidero-
phores. Some fungi use ferric reductases or low molecular
mass iron reductants to reduce ferric to ferrous iron, and
extract it from the extracellular environment. Such mecha-
nisms have been documented in C. albicans, Histoplasma cap-
sulatum [15], and Cryptococcus neoformans [16].
Zygomycetes and Iron
Zygomycosis is a difﬁcult-to-treat systemic fungal infection,
caused by Zygomycetes, with a high mortality rate, ranging
from 50% to 100%. The disease in any clinical form is charac-
terized by the propensity of Zygomycetes for vascular inva-
sion and dissemination, commonly resulting in thrombosis
and tissue necrosis. The infection can rapidly extend from
the paranasal sinuses to the oral cavity, to the orbit, and
intracranially, sometimes producing cavernous sinus throm-
bosis [17]. Zygomycosis almost always occurs among
patients with a pre-existing immune defect, although rare
cases have been reported among apparently normal individu-
als [18]. In the majority of cases, the disease is rapidly pro-
gressive and eventually fatal, unless prompt treatment with
high doses of liposomal amphotericin B (LAmB), in asso-
ciation with careful surgical debridement, can change the
otherwise dismal clinical course. Because the spectrum of
diseases, for which immunosuppressive treatments are used,
has enlarged, the application particularly non-myeloblative
preparatory regimens is increasing [19] and systemic anti-
fungal prophylaxis with agents, ineffective against zygomyce-
tes is broadened, the incidence of zygomycosis appears to
have increased in the last few decades [20].
Well-recognized predisposing factors for zygomycosis are
diabetes mellitus (especially when complicated by ketoacido-
sis), treatment with corticosteroids, immunosuppression,
prolonged leukopenia (neutropenia and lymphopenia), recent
chemotherapy and tissue damage, history of allogeneic stem
cell transplantation, and chronic graft-versus-host-disease. A
common denominator of almost all of these conditions is the
presence of excessive iron overload, as a high tissue iron
burden, as elevated serum transferrin, and also as increased
non-transferrin-bound iron. In particular, it has been sug-
gested that diabetic ketoacidosis and acidoses of any aetiol-
ogy predispose to zygomycosis by facilitating the dissociation
of iron from iron-carrying proteins, thus providing increased
available free iron [21]. Elevated serum and tissue iron have
a tremendous impact on the growth and development of
Zygomycetes [22]. There are reports of fast Mucor growth
with formation of intra-arterial thrombi among immunocom-
promised patients with iron overload [23,24]. In a retrospec-
tive analysis of 263 allotransplanted patients, ﬁve cases of
invasive zygomycosis were identiﬁed. In comparison with
matched controls, these patients had signiﬁcantly higher
serum ferritin levels, transferrin saturation, and number of
previously transfused red blood cell units. It is of note that
Zygomycetes possess a speciﬁc high-afﬁnity iron permease
gene (RFTR1), which has been characterized and cloned
[25]. Analysis of the polymorphisms of this gene, performed
by using a combined PCR ampliﬁcation and sequencing
method, has recently been proposed as a tool for the molec-
ular identiﬁcation of the different Zygomycete species [26].
The Role of Deferoxamine (DFO)
The well-documented and repeatedly reported increased
susceptibility to zygomycosis of haemodialysis patients during
treatment with DFO, an iron chelator that is capable of
removing tissue iron, initially appeared to be a paradox
[27,28]. It became clear, however, that although DFO che-
lates iron, from the perspective of Zygomycetes it is a xeno-
siderophore, as fungal siderophores have higher afﬁnity for
iron than DFO and therefore are capable of easily and effec-
tively detaching iron from it and providing it to the fungi
[7,29]. This ability is particularly prominent in Zygomycetes,
and these species can remove eight and 40 times greater
amounts of iron from DFO than A. fumigatus and C. albicans,
respectively.
The rapid and effective iron uptake by Zygomycetes results
in rapid growth in serum. The growth of Rhizopus rhizopodifor-
mis spores, isolated from a dialysis patient with zygomycosis
while on DFO therapy, was studied in an iron-deﬁcient med-
ium containing human serum at increasing concentrations and
with human serum enriched with different concentrations of
ferrioxamine (DFO–iron complex). A concentration of 40%
human serum inhibited fungal growth by >50%. However, in
the presence of serum, ferrioxamine produced signiﬁcant
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growth stimulation at 24 h that persisted at 48 h [29]. The
effect of human serum and of ferrioxamine on the growth of
Rhizopus found in this study is demonstrated in Fig. 1. Data
from animal models emphasize the exceptional requirement of
iron for Rhizopus pathogenicity, as administration of DFO or
free iron worsens the survival of animals infected with Rhizo-
pus, but not with Candida [30].
DFO has been demonstrated to act as a xenosiderophore
in Rhizopus, other members of the Mucorales, and probably
other pathogenic fungi. It is assumed that fungal enzymes or
siderophores are able to speciﬁcally bind to ferrioxamine
and, because they have higher afﬁnity for iron, strip iron
from ferrioxamine and facilitate iron uptake by the fungi. A
similar phenomenon does not take place with deferiprone
[31]. The susceptibility to zygomycosis of dialysis patients
treated with DFO could be attributed to the facts that ura-
emia results in signiﬁcant retention of the iron-loaded fer-
rioxamine in the circulation, and that this is removed during
dialysis, causing patients’ serum to lose its fungistatic power
and be transformed to a favourable culture medium for
Zygomycetes [32].
The Role of Newer Iron Chelators
There are two newer iron chelators in general use, deferi-
prone (DFP) (Ferriprox, DFP; Apotex, Toronto, Canada),
which was introduced in the 1990s, and deferasirox (DFX)
(Exjade; Novartis–DFX, Basel, Switzerland), which was intro-
duced more recently. Both drugs are effective iron chelators
in clinical practice, but their use has not been associated with
increased numbers of fungal infections or, particularly, of
zygomycoses. The reason for this discrepancy, as compared
with DFO, may be the different chemical structures and
chelating afﬁnities of the three drugs. DFO is an exadentate
chelator, has a higher molecular mass, and shows a molecu-
lar chelating relationship with the ferric iron of 1 : 1, which
implies that each DFO molecule chelates one ferric ion. DFP
is a bidentate chelator, and its chelating relationship is 3 : 1,
meaning that each ferric iron is chelated by three molecules
of DFP. DFX is a tridentate chelator, and its chelating rela-
tionship is 2 : 1, meaning that each ferric iron is chelated by
two molecules of DFX) [33]. The chemical structures of the
three iron chelators are shown in Fig. 2.
The two newer iron chelators do not act as xenosidero-
phores, apparently because the fungal iron uptake systems are
incapable of detaching iron from them. This could be due
either to inadequate molecular access, as they are smaller
molecules than DFO, or to their higher afﬁnity for iron, which
means that DFP and DFX might form more stable chemical
structures with iron that are not destabilized in the presence
of fungal enzymes or siderophores. Moreover, the demon-
stration of clear inhibitory activity of the two newer chelators
on fungal growth suggests that these molecules are probably
capable of detaching iron from the fungal iron uptake mole-
cules and holding it more strongly. This has been proven
in vivo, using animal models of zygomycosis, in which treat-
ment of Rhizopus-infected mice or guinea pigs with DFP mark-
edly improved survival [31]. In cultures of Rhizopus oryzae,
DFP has fungistatic activity at 24 h, conﬁrmed at 48 h [34].
The introduction of DFX and the recognition of the safety
and efﬁcacy proﬁle of the drug encouraged its use in
sporadic cases of systemic zygomycosis and in experimental
animal studies. DFX induces an iron-starvation response in
R. oryzae and activates RFTR1 expression. Addition of DFX
to cultures of different members of the Mucorales produced
a fungicidal effect, which was reversed by the addition of
iron. The MIC90s of DFX against various Mucor spp. were
much lower than the levels achieved by the administration of
the usual daily dose of 20 mg/kg. Treatment with routine
FIG. 1. Effect of human serum and of ferriox-
amine on the growth of Rhizopus microsporus.
Spores of Rhizopus were cultivated for 24 h at
37C in standard BDM culture medium alone
(a), in BDM with 40% human serum (b), or in
BDM with 40% serum + 1 lM Fe deferox-
amine (Fe.DFO) (c). Lugol stain ·500. Reprin-
ted from reference [29].
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doses of DFX of diabetic ketoacidotic mice infected with
spores of R. oryzae led to signiﬁcantly improved survival as
compared with controls, and resulted in a more than
ten-fold reduction of brain and kidney fungal burden as
compared with placebo-treated animals. The kidneys of
DFX-treated mice had no visible hyphae and there was an
effective neutrophil inﬂammatory reaction, whereas kidneys
of placebo-treated mice had extensive ﬁlamentous fungi and
manifested a poor or complete absence of a neutrophil
inﬂammatory response [35].
In another experiment, mice infected intranasally with 107
spores of R. oryzae were treated for 7 days, starting 24 h
post-infection, with either DFX 10 mg/kg twice daily or pla-
cebo. As controls, infected or uninfected mice were treated
with DFO 50 mg/kg. DFX was signiﬁcantly more protective
than placebo or DFO. As expected, DFO worsened the sur-
vival of infected mice, although it had no effect on uninfected
mice (Fig. 3). Treatment with DFX resulted in signiﬁcantly
increased Th1 and Th2 splenocyte subpopulations, and in sig-
niﬁcantly higher splenic and kidney levels of the proinﬂamma-
tory cytokines tumour necrosis factor-a and interferon-c, than
those in mice treated with saturating iron or placebo [35].
Iron Chelators as Adjuvant Treatment in
Systemic Zygomycosis
In a mouse model of zygomycosis, animals were infected with
R. oryzae spores, and 24 h later were treated with DFP at dose
levels of 50, 100 or 200 mg/kg every day or every other day.
The dose of 100 mg/kg every other day resulted in a signiﬁcant
survival advantage in DFP-treated mice as compared with pla-
cebo-treated animals. The other dose schedules were either
ineffective or toxic. The survival advantage was comparable to,
although lower than, that of LAmB-treated mice. Both drugs
signiﬁcantly reduced the brain fungal burden as compared with
placebo. The beneﬁcial effect of DFP was abrogated when
animals were given ferric chloride [34]
In a similar mouse model with established zygomycosis,
the administration of DFX was associated with efﬁcacy
comparable to that of LAmB. DFX has shown efﬁcacy in
neutropenic and diabetic ketoacidotic mice with zygomycosis.
In these experiments, DFX at a daily dose of 20 mg/kg
initiated 24 h after infection was synergistic with LAmB at
a high-dose schedule of 15 mg/kg daily in the reduction of
FIG. 2. Stereochemical structure of the three available iron chelators. Stereochemical structures and molecular chelating relationships of the
three available iron chelators. Deferoxamine (DFO) has a higher molecular mass and is a hexadentate chelator; that is, each molecule holds one
ferric iron (chelating ratio 1 : 1). Deferasirox (DFX) has a lower molecular mass and is a tridentate chelator; that is, two DFX molecules hold
each ferric iron (chelating ratio 2 : 1). Deferiprone (DFP) has an even lower molecular mass and is a bidentate chelator; that is, three DFP mole-
cules chelate each ferric iron (chelating ratio 3 : 1).
FIG. 3. Effect of deferoxamine (DFO)and deferasirox (DFX) treat-
ment on the survival of mice infected with Rhizopus. Survival of diabetic
ketoacidotic mice infected intranasally with 107 spores of Rhizopus
oryzae and 24 h later treated with placebo (n = 13), DFX 10 mg/kg
twice daily (n = 13), or DFO 50 mg/kg (n = 8). DFX protected the
animals as compared with placebo-treated mice (p < 0.047) or DFO-
treated mice (p < 0.009). Reprinted from reference [35].
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fungal burden from the brain and the kidney. Moreover, the
combination of the two drugs signiﬁcantly improved survival
time as compared with placebo or each drug separately
(Fig. 4) [35].
The use of iron chelators as adjuvant treatment in sys-
temic zygomycosis and other mycoses appears to be rational,
and has been shown to be effective in sporadic cases. Reed
et al. reported a case of a 40-year-old diabetic patient with
aggressive rhinocerebral zygomycosis and progressive central
nervous system involvement, despite combination treatment
with high-dose LAmB plus caspofungin and surgical debride-
ment [36]. As brain magnetic resonance imaging showed
new parenchymal lesions and left cavernous sinus thrombo-
sis, he was given a 7-day salvage treatment with DFX
1000 mg daily. A new brain magnetic resonance imaging scan
showed signiﬁcant improvement, and treatment with LAmB
was discontinued. The patient, 4 months following treatment
discontinuation, remained in good condition without any
neurological deﬁcit. This is the ﬁrst reported case of zygo-
mycosis being successfully treated with a combination of clas-
sical antifungal treatment and an iron chelator [36].
We recently treated a 37-year-old male with acute
lymphoblastic leukaemia in remission following a matched-
related allogeneic transplant, who manifested concurrent rhi-
nocerebral and pulmonary zygomycosis, while undergoing
treatment with corticosteroids for extensive chronic graft-
versus-host disease. The patient was treated with a combina-
tion of LAmB 10 mg/kg, posaconazole and deferasirox
10 mg/kg twice daily. Restricted intranasal and intrasinus sur-
gical debridement was also applied repeatedly. The patient
responded very well, with rapid defervescence, resolution of
pain and chymosis, and disappearance of the dense pulmo-
nary and sinonasal inﬁltrates. He is now receiving weekly
consolidation boosting of LAmB as outpatient therapy
(A. Symeonidis, unpublished data).
In other cases, however, iron chelation treatment has
been unsuccessful [37]. Therefore, the possible beneﬁt of
iron chelation as an adjuvant treatment in systemic fungal
infections, and particularly in zygomycosis, has to be tested
in a prospective randomized trial.
Conclusions
There are still many open issues for clariﬁcation: should iron
chelation form part of the antifungal treatment in all systemic
mycoses or only in zygomycosis? Will this treatment permit
shortening of the duration of treatment with classical antifun-
gal agents? Which are the best iron chelators and what are
their optimal doses? Should systemic antifungal prophylaxis
be administered to patients undergoing intravenous iron che-
lation therapy with DFO? Are some speciﬁc patient popula-
tions less or more prone to DFO-induced zygomycosis?
Currently, there is an ongoing prospective randomized
trial, with the code number NCT00419770, introduced by
the Los Angeles Biomedical Research Institute, the Deferasi-
rox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor
Study). This study has been open since December 2007, and
recruits patients with zygomycosis in an effort to answer
some of the above-mentioned questions.
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